Amgen, Astra post late-stage trial win for asthma drug Tezspire in swallowing disorder

Phase 3positiveTezspirePositive

AI Analysis

Summary

Amgen and Astra announced a late-stage trial success for Tezspire in treating asthma patients with swallowing disorders. The positive Phase 3 data represents a potential expansion of the drug's therapeutic applications.

Clinical Trial Data

Phase

Primary Endpoint

Met

Importance:7/10

Sentiment:

0.75

Phase 3Trial WinTezspireAsthmaPartnership

Related Companies

$AMGN

Read the original article

Published by Seeking Alpha Healthcare on August 28, 2026 12:18 PM

Read Original